Psychedelics policy moves stocks

Psychedelic stocks jumped after the White House signed an April 18 executive order aimed at speeding research, review and access for some mental-illness treatments. (whitehouse.gov) The order says the Food and Drug Administration should prioritize certain psychedelic drugs that already have Breakthrough Therapy designation, and it tells the FDA and Drug Enforcement Administration to create a Right to Try pathway for eligible patients seeking investigational psychedelic drugs, including ibogaine compounds. (whitehouse.gov) The same fact sheet says the Department of Health and Human Services must set aside $50 million through the Advanced Research Projects for Health, or ARPA-H, to match state spending on psychedelic research for serious mental illness. (whitehouse.gov) Investors immediately treated the order as a sector catalyst. Psyence Biomedical closed at $7.60 on April 17 after trading as high as $10.53 that day, while AtaiBeckley closed at $4.03, according to market data pages updated after the move. (marketbeat.com) (google.com) Psyence BioMed is a small Nasdaq-listed developer of psilocybin and ibogaine therapies, so policy headlines can move the stock sharply when traders think federal agencies may clear a faster path for studies or future approvals. The company said April 18 that it welcomed the executive action and pointed to its ibogaine work. (markets.businessinsider.com) AtaiBeckley is a larger psychedelic-drug developer created by the 2025 combination of atai Life Sciences and Beckley Psytech. Its lead program, BPL-003 for treatment-resistant depression, holds Breakthrough Therapy designation and remains on track for Phase 3 initiation in the second quarter of 2026, the company said in March. (ir.atai.com) That detail matters because the White House order is tied directly to Breakthrough-designated psychedelic drugs, not to every company working in the field. The administration’s fact sheet says priority vouchers would go to “appropriate” psychedelic drugs that meet the National Priority Voucher Program criteria. (whitehouse.gov) Psyence’s nearer-term clinical work is not centered on U.S. approval. The company said on April 10 that it had expanded its Australian site network to five locations for an ongoing Phase IIb natural psilocybin trial in palliative oncology patients. (markets.businessinsider.com) The order also does not approve any psychedelic drug. It directs agencies to speed review, expand trial participation and prepare for possible rescheduling after successful Phase 3 trials and Food and Drug Administration approval, where appropriate. (whitehouse.gov) That leaves traders betting on policy momentum while regulators still control the harder steps: late-stage trial results, formal review and any eventual label approval. For now, the clearest immediate effect is that Washington moved psychedelic medicine from a niche biotech theme into the center of a one-day stock trade. (whitehouse.gov) (google.com)